Page 27 - Read Online
P. 27

Page 6 of 13             Wilson et al. Plast Aesthet Res. 2025;12:8  https://dx.doi.org/10.20517/2347-9264.2024.135

               Table 1. Summary of comorbidities of < 20% TBSA (Series B) patient cohort
                      Total                        Significant cardiac, respiratory,
                Patient           Diabetes Malignancy                      Other
                      comorbidities                kidney disease (CKD 3b/4/5)
                1     1           N       N        N                       Spinal injury
                2     3           N       N        N                       Chronic kidney disease, hypertension, cataracts
                3     0           N       N        N                       n
                4     1           N       N        N                       HTN
                5     5           Y       N        N                       Diabetic neuropathy, cataracts, HTN,
                                                                           hyperlipidemia
                6     3           N       Y        N                       Hypertension, stroke
                7     1           N       N        N                       arthritis
                8     0           N       N        N                       n
                9     8           Y       N        MI, HFREF               Cataracts, hypertension, chronic kidney disease,
                                                                           peripheral neuropathy
                10    1           N       N        N                       stroke
                11    3           Y       N        N                       Hypercholesterolemia, hypertension
                12    -           -       -        -                       -
                13    -           -       -        -                       -
                14    4           Y       N        MI                      Chronic kidney disease, benign prostatic
                                                                           hyperplasia, hypercholesterolemia, hypertension
                15    7           Y       N        N                       Chronic kidney disease, benign prostatic
                                                                           hyperplasia, hypercholesterolemia, hypertension
                16    4           Y       N        MI, HFREF               Hypercholesterolemia
                17    3           Y       N        MI                      Barrett’s esophagus, pancreatitis, benign
                                                                           prostatic hyperplasia
                18    6           Y       N        MI, HFREF               Tension headaches, visual impairment,
                                                                           hypertension
                19    3           N       N        N                       Bipolar, hypertension, hypothyroidism
                20    1           N       N        N                       depression
                21    -           -       -        -                       -
                23    1           N       N        N                       HTN
                24    0           N       N        N                       n
                25    5           N       N        MI                      Cyclical vomiting, anxiety, depression,
                                                                           hypertension
                26    1           N       N        N                       Mental health disorder
                27    4           N       N        N                       Atrial fibrillation, dementia, hypertension,
                                                                           osteoporosis
               TBSA: Total body surface area; CKD: chronic kidney disease; HTN: hypertension; MI: myocardial infarction; HFREF: heart failure with reduced
               ejection fraction.

               greater contractility of thicker split skin grafts [29,30] . A key advantage of Meek is its ability to provide a precise
               calculation of the TBSA that can be covered by a donor site of a given size. For instance, a 20 cm × 20 cm
               donor site expanded at a 1:4 ratio can cover a 40 cm × 40 cm wound bed.

               One potential drawback of Meek is the surgical time required. This paper does not specifically assess
               operative duration, while data from a previous series at our center demonstrated that the Meek technique,
               on average, required 17 min less than conventional meshed grafting in comparable patients with similar
               wound sizes.  Additionally, published literature supports the observation that Meek grafting can reduce
                          [1]
               operative time. [7,31]  We acknowledge that there is a learning curve associated with this technique and that, in
               addition to this, its success depends on appropriate planning and staffing. We believe the reduced surgical
               time in our series is largely due to an optimized workflow: by harvesting the donor site at the beginning of
               the procedure, the primary surgeon can debride the burn wound while a trained colleague performs the
   22   23   24   25   26   27   28   29   30   31   32